Drugs / NPC-06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05480553 | Aug 2022 → May 2023 | herpes zoster | Nobelpharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03773055 Comparator | Apr 2019 → Sep 2020 | neuropathy, painful | Nobelpharma | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPC-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480553 ↗ |
| Known as | fosphenytoin sodium hydrate | “To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in patients with pain associated with acute herpes zoster in a placebo-controlled,...” NCT05480553 ↗ |
| Route | Intravenous | “18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage” NCT03773055 ↗ |